Compare Novartis AG (NVS) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Synopsys, Inc. — how do they compare? Novartis AG trades at $142.86 (market cap $268.57B), while Synopsys, Inc. trades at $505 (market cap $95.39B). The key difference: Novartis AG is far larger — about 2.8× Synopsys, Inc.'s market cap, and Novartis AG pays a 3.31% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Synopsys, Inc. for 71 Days on average.
| NVS | SNPS | |
|---|---|---|
Market Cap | $268.57B | $95.39B |
Volume | 1,532,573 | 3,374,903 |
Sector | Health | Technology |
52-Week High | $168.62 | $534.56 |
52-Week Low | $121.80 | $367.70 |
Typical Hold Time | 82 Days | 71 Days |
Enterprise Value | $309.89B | $102.62B |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
Synopsys (SNPS) trades at $502.67, down 0.49% on the day, but maintains strong bullish momentum with recent AI-driven partnerships and earnings beats. The stock shows robust fundamentals with Q2 2026 EPS of $3.91 beating expectations by 6.5%, supported by a 72.38% gross margin. Technical indicators show bullish moving averages but overbought RSI levels above 89, with key support at $500 and resistance at $505. Recent announcements with OpenAI and Amazon have driven significant investor optimism and price target upgrades.
The outlook remains positive with 93% analyst buy ratings and a $572.54 consensus target suggesting 14% upside. Key opportunities include AI-driven chip design growth and Ansys integration synergies, while risks include high valuation (P/E 87.7) and execution challenges in large-scale partnerships. The stock's proximity to all-time highs requires careful monitoring of earnings delivery and competitive pressures in the EDA market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
